Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
5.625 EUR | +4.55% | +3.89% | -15.51% |
Apr. 03 | Nanobiotix completes escalation portion of 2020-0123 study | CF |
Apr. 02 | Nanobiotix Completes Dose Escalation Segment of Phase 1 Study Targeting Non-Small Cell Lung Cancer | MT |
Sales 2023 * | 15.31M 16.3M | Sales 2024 * | 19.79M 21.07M | Capitalization | 253M 270M |
---|---|---|---|---|---|
Net income 2023 * | -42M -44.72M | Net income 2024 * | -42M -44.72M | EV / Sales 2023 * | 18.1 x |
Net Debt 2023 * | 24.2M 25.77M | Net Debt 2024 * | 24.35M 25.93M | EV / Sales 2024 * | 14 x |
P/E ratio 2023 * |
-6.29
x | P/E ratio 2024 * |
-6.75
x | Employees | 101 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 99.58% |
Latest transcript on Nanobiotix
1 day | +3.25% | ||
1 week | +2.87% | ||
Current month | -2.54% | ||
1 month | -2.37% | ||
3 months | -21.76% | ||
6 months | -7.72% | ||
Current year | -16.34% |
Managers | Title | Age | Since |
---|---|---|---|
Laurent Lévy
CEO | Chief Executive Officer | 53 | 03-03-03 |
Bart van Rhijn
DFI | Director of Finance/CFO | 52 | 21-05-31 |
Chief Tech/Sci/R&D Officer | - | 22-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Phillips
CHM | Chairman | 58 | 21-05-24 |
Enno Spillner
BRD | Director/Board Member | 55 | 14-06-17 |
Alain Herrera
BRD | Director/Board Member | 74 | 11-06-22 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 5.625 | +4.55% | 27 574 |
24-04-22 | 5.38 | +2.48% | 37,347 |
24-04-19 | 5.25 | +1.06% | 33,339 |
24-04-18 | 5.195 | -0.76% | 35,872 |
24-04-17 | 5.235 | -3.06% | 56,248 |
Real-time Euronext Paris, April 23, 2024 at 03:07 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.34% | 270M | |
-0.02% | 42.11B | |
+43.29% | 40.08B | |
+5.04% | 40B | |
-11.32% | 26.87B | |
+5.25% | 24.58B | |
-23.83% | 18.44B | |
-1.62% | 11.94B | |
+22.75% | 11.66B | |
+6.44% | 11.01B |
- Stock Market
- Equities
- NANO Stock